Latest Pharma Insights
White House Requests FDA Food Programs Spending Boost But Lower Overall FY 2027 Budget
Request would set FDA’s next budget at $7.23bn after it received just short of $7bn for FY2026; includes $3.306bn in direct appropriations, $47.8m less than in the current budget, and increases total support from user fees by $280m to $3.92bn.
HBW Insight - April 9, 2026
Request would set FDA’s next budget at $7.23bn after it received just short of $7bn for FY2026; includes $3.306bn in direct appropriations, $47.8m less than in the current budget, and increases total support from user fees by $280m to $3.92bn.
HBW Insight - April 9, 2026
Children’s Beauty Boom Signals Caution for Brands In Europe
Beauty products sold in Europe face scrutiny over children’s growing use of skin care and cosmetics as regulators examine safety obligations under EU law and investigate marketing practices targeting minors.
HBW Insight - April 9, 2026
Beauty products sold in Europe face scrutiny over children’s growing use of skin care and cosmetics as regulators examine safety obligations under EU law and investigate marketing practices targeting minors.
HBW Insight - April 9, 2026
Finance Watch: Alternative Funding Agreements Abound, From Small To Large Biopharma
Public Company Edition: Some firms – including Johnson & Johnson and Opus Genetics – are pursuing funding alternatives, including royalty financings and other options, while Celldex raised $345m from a straightforward follow-on offering.
Scrip - April 9, 2026
Public Company Edition: Some firms – including Johnson & Johnson and Opus Genetics – are pursuing funding alternatives, including royalty financings and other options, while Celldex raised $345m from a straightforward follow-on offering.
Scrip - April 9, 2026
Roche And C4 Expand Alliance Into Degrader-Antibody Conjugate Work
Partnered since 2016 on targeted protein degradation, Roche and C4 now will combine technologies and capabilities to develop DAC therapeutics for cancer.
Scrip - April 9, 2026
Partnered since 2016 on targeted protein degradation, Roche and C4 now will combine technologies and capabilities to develop DAC therapeutics for cancer.
Scrip - April 9, 2026
Execs On The Move: March 30–April 3, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 9, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 9, 2026
Deals Shaping The Medtech And Diagnostics Industries, March 2026
An interactive look at medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
Medtech Insight - April 9, 2026
An interactive look at medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
Medtech Insight - April 9, 2026
FDA Challenges Innovators To Help Reduce Hospital Readmissions By Advancing At Home Care
The US FDA wants the best and brightest medtech innovators to help the agency bring the latest medical device technologies to patients where they live. A device center initiative seeks to accelerate the development of new device technologies to help cut down on hospital readmissions.
Medtech Insight - April 9, 2026
The US FDA wants the best and brightest medtech innovators to help the agency bring the latest medical device technologies to patients where they live. A device center initiative seeks to accelerate the development of new device technologies to help cut down on hospital readmissions.
Medtech Insight - April 9, 2026
Assertio Agrees To Buyout By Garda Therapeutics
The company will also sell nearly all of its marketed assets, except the drug Rolvedon, to Cosette Pharmaceuticals, including Sympazan for Lennox-Gastaut syndrome.
Scrip - April 9, 2026
The company will also sell nearly all of its marketed assets, except the drug Rolvedon, to Cosette Pharmaceuticals, including Sympazan for Lennox-Gastaut syndrome.
Scrip - April 9, 2026
CorTec’s CEO Says FDA Breakthrough Marks Shift To Therapeutic BCI For Stroke
CorTec secured US FDA breakthrough device designation for an implantable BCI that restores motor function in stroke patients. With the device implanted in two patients and a third to come, CorTec now eyes larger trials and a $40m-$50m funding raise.
Medtech Insight - April 9, 2026
CorTec secured US FDA breakthrough device designation for an implantable BCI that restores motor function in stroke patients. With the device implanted in two patients and a third to come, CorTec now eyes larger trials and a $40m-$50m funding raise.
Medtech Insight - April 9, 2026
Executives On The Move: Orion Gets Senior Executive From Johnson & Johnson
Recent changes in the industry include internal moves at Takeda, Moderna, Gilead Sciences and Bayer, plus Proxygen gets a new CSO from Blueprint Medicines.
Scrip - April 9, 2026
Recent changes in the industry include internal moves at Takeda, Moderna, Gilead Sciences and Bayer, plus Proxygen gets a new CSO from Blueprint Medicines.
Scrip - April 9, 2026
AI Act Updates Risk ‘Consumer Harm’ From Medical Devices, EU Civil Society Orgs Say
An open letter says recent EU AI Act amendments create “loopholes” that leave some elements of AI-enabled medical devices under-regulated.
Medtech Insight - April 9, 2026
An open letter says recent EU AI Act amendments create “loopholes” that leave some elements of AI-enabled medical devices under-regulated.
Medtech Insight - April 9, 2026
Another One Bites The Dust: Iterum Shuts Shop As Antibiotic Woes Drag On
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
Scrip - April 9, 2026
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
Scrip - April 9, 2026
Opella Sees Role For Evidence?Based Self?Care In Early MASLD Care
New clinical evidence suggests evidence?based self?care can play a meaningful role in managing MASLD, a common fatty liver condition linked to obesity and diabetes, supporting lifestyle change and opening growth opportunities in an underdeveloped liver health category.
HBW Insight - April 9, 2026
New clinical evidence suggests evidence?based self?care can play a meaningful role in managing MASLD, a common fatty liver condition linked to obesity and diabetes, supporting lifestyle change and opening growth opportunities in an underdeveloped liver health category.
HBW Insight - April 9, 2026
People On The Move: Appointments At Barentz, iHerb, Lonza
A round up of the latest European health & wellness people moves: Barentz names first Human Nutrition EMEA VP; iHerb hires Europe general manager; Lonza adds experience to board.
HBW Insight - April 9, 2026
A round up of the latest European health & wellness people moves: Barentz names first Human Nutrition EMEA VP; iHerb hires Europe general manager; Lonza adds experience to board.
HBW Insight - April 9, 2026
Singapore’s Asian Population Cohort Dataset To Move Forward With Seer’s Proteograph Platform
Precision medicine has a diversity gap – relatively few biomarker datasets to date have strong relevance for non-Western populations. Seer’s Proteograph selection for PRECISE-SG100K, a 100,000-person Singapore cohort, is one of the most direct attempts yet to address that at population scale.
Medtech Insight - April 9, 2026
Precision medicine has a diversity gap – relatively few biomarker datasets to date have strong relevance for non-Western populations. Seer’s Proteograph selection for PRECISE-SG100K, a 100,000-person Singapore cohort, is one of the most direct attempts yet to address that at population scale.
Medtech Insight - April 9, 2026
‘Eggs Solve All Of Those Problems’ – How Neion Bio Is Seeking To Shake Up Biosimilar Manufacturing
As Neion Bio announced its new technology platform to manufacture recombinant biologics in eggs – accompanied by an initial multi-product biosimilar deal – the firm’s founders set out their goals in an exclusive interview with Generics Bulletin.
Generics Bulletin - April 9, 2026
As Neion Bio announced its new technology platform to manufacture recombinant biologics in eggs – accompanied by an initial multi-product biosimilar deal – the firm’s founders set out their goals in an exclusive interview with Generics Bulletin.
Generics Bulletin - April 9, 2026
Generics Remain ‘Critical Foundation’ For Arcera
Isabel Afonso, CEO of Arcera, talks to Generics Bulletin about how off-patent products remain a “critical foundation” for the UAE-based firm even as it expands into increasingly innovative areas.
Generics Bulletin - April 9, 2026
Isabel Afonso, CEO of Arcera, talks to Generics Bulletin about how off-patent products remain a “critical foundation” for the UAE-based firm even as it expands into increasingly innovative areas.
Generics Bulletin - April 9, 2026
FDA Budget Offers Update On Domestic Incentives For Para IV Filings
The US FDA’s latest annual budget request includes proposals that would allow firms to file Paragraph IV ANDAs more quickly if they manufacture in the US, as well as to make it easier to develop generic drug-device combinations and to deem all biosimilars interchangeable.
Generics Bulletin - April 9, 2026
The US FDA’s latest annual budget request includes proposals that would allow firms to file Paragraph IV ANDAs more quickly if they manufacture in the US, as well as to make it easier to develop generic drug-device combinations and to deem all biosimilars interchangeable.
Generics Bulletin - April 9, 2026
Biocon Launches Held-Back Denosumab Biosimilars In The US
Even though Biocon settled with originator Amgen last autumn, the firm has just now launched its biosimilar rivals to the Prolia/Xgeva brands.
Generics Bulletin - April 9, 2026
Even though Biocon settled with originator Amgen last autumn, the firm has just now launched its biosimilar rivals to the Prolia/Xgeva brands.
Generics Bulletin - April 9, 2026
MSN Deal Ends Trulance Dispute, Signals Launch Pathway
MSN and Bausch have settled their long-running Trulance patent dispute, ending litigation tied to Paragraph IV challenges after trial and parallel PTAB proceedings.
Generics Bulletin - April 9, 2026
MSN and Bausch have settled their long-running Trulance patent dispute, ending litigation tied to Paragraph IV challenges after trial and parallel PTAB proceedings.
Generics Bulletin - April 9, 2026
Deals Shaping The Industry, March 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026
Podcast: How Israel Is Positioning Itself As A Global Innovation Hub
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026
US 100% Tariffs Loom Over Approved Chinese Innovative Drugs
Under the new US tariff regime on imported pharmaceuticals, it’s unclear whether or how steep the extra duties may be on six Chinese innovative drugs that have been approved by the US FDA since 2023.
Scrip - April 9, 2026
Under the new US tariff regime on imported pharmaceuticals, it’s unclear whether or how steep the extra duties may be on six Chinese innovative drugs that have been approved by the US FDA since 2023.
Scrip - April 9, 2026
Outgoing PhRMA CEO Ubl Fought, Shaped Policies and Politics Around Price Controls
Ubl notched wins and losses on drug pricing reform during his more than 10 years at the trade association.
Scrip - April 9, 2026
Ubl notched wins and losses on drug pricing reform during his more than 10 years at the trade association.
Scrip - April 9, 2026
Researchers Make Case To Expand Medication Abortion Access But Note OTC Approval Unlikely
Researchers from Advancing New Standards in Reproductive Health at University of California, San Francisco, say mifepristone/misoprostol medication abortion “likely meets” FDA criteria for OTC sales but acknowledge it’s unlikely they will become available nonprescription.
HBW Insight - April 9, 2026
Researchers from Advancing New Standards in Reproductive Health at University of California, San Francisco, say mifepristone/misoprostol medication abortion “likely meets” FDA criteria for OTC sales but acknowledge it’s unlikely they will become available nonprescription.
HBW Insight - April 9, 2026
Finance Watch: Alternative Funding Agreements Abound, From Small To Large Biopharma
Public Company Edition: Some firms – including Johnson & Johnson and Opus Genetics – are pursuing funding alternatives, including royalty financings and other options, while Celldex raised $345m from a straightforward follow-on offering.
Scrip - April 9, 2026
Public Company Edition: Some firms – including Johnson & Johnson and Opus Genetics – are pursuing funding alternatives, including royalty financings and other options, while Celldex raised $345m from a straightforward follow-on offering.
Scrip - April 9, 2026
Roche And C4 Expand Alliance Into Degrader-Antibody Conjugate Work
Partnered since 2016 on targeted protein degradation, Roche and C4 now will combine technologies and capabilities to develop DAC therapeutics for cancer.
Scrip - April 9, 2026
Partnered since 2016 on targeted protein degradation, Roche and C4 now will combine technologies and capabilities to develop DAC therapeutics for cancer.
Scrip - April 9, 2026
Assertio Agrees To Buyout By Garda Therapeutics
The company will also sell nearly all of its marketed assets, except the drug Rolvedon, to Cosette Pharmaceuticals, including Sympazan for Lennox-Gastaut syndrome.
Scrip - April 9, 2026
The company will also sell nearly all of its marketed assets, except the drug Rolvedon, to Cosette Pharmaceuticals, including Sympazan for Lennox-Gastaut syndrome.
Scrip - April 9, 2026
Executives On The Move: Orion Gets Senior Executive From Johnson & Johnson
Recent changes in the industry include internal moves at Takeda, Moderna, Gilead Sciences and Bayer, plus Proxygen gets a new CSO from Blueprint Medicines.
Scrip - April 9, 2026
Recent changes in the industry include internal moves at Takeda, Moderna, Gilead Sciences and Bayer, plus Proxygen gets a new CSO from Blueprint Medicines.
Scrip - April 9, 2026
Another One Bites The Dust: Iterum Shuts Shop As Antibiotic Woes Drag On
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
Scrip - April 9, 2026
High post-approval costs, weak returns and low initial uptake continue to weigh on antibiotics.
Scrip - April 9, 2026
US 100% Tariffs Loom Over Approved Chinese Innovative Drugs
Under the new US tariff regime on imported pharmaceuticals, it’s unclear whether or how steep the extra duties may be on six Chinese innovative drugs that have been approved by the US FDA since 2023.
Scrip - April 9, 2026
Under the new US tariff regime on imported pharmaceuticals, it’s unclear whether or how steep the extra duties may be on six Chinese innovative drugs that have been approved by the US FDA since 2023.
Scrip - April 9, 2026
Outgoing PhRMA CEO Ubl Fought, Shaped Policies and Politics Around Price Controls
Ubl notched wins and losses on drug pricing reform during his more than 10 years at the trade association.
Scrip - April 9, 2026
Ubl notched wins and losses on drug pricing reform during his more than 10 years at the trade association.
Scrip - April 9, 2026
Execs On The Move: March 30–April 3, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 9, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 9, 2026
Deals Shaping The Medtech And Diagnostics Industries, March 2026
An interactive look at medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
Medtech Insight - April 9, 2026
An interactive look at medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
Medtech Insight - April 9, 2026
FDA Challenges Innovators To Help Reduce Hospital Readmissions By Advancing At Home Care
The US FDA wants the best and brightest medtech innovators to help the agency bring the latest medical device technologies to patients where they live. A device center initiative seeks to accelerate the development of new device technologies to help cut down on hospital readmissions.
Medtech Insight - April 9, 2026
The US FDA wants the best and brightest medtech innovators to help the agency bring the latest medical device technologies to patients where they live. A device center initiative seeks to accelerate the development of new device technologies to help cut down on hospital readmissions.
Medtech Insight - April 9, 2026
CorTec’s CEO Says FDA Breakthrough Marks Shift To Therapeutic BCI For Stroke
CorTec secured US FDA breakthrough device designation for an implantable BCI that restores motor function in stroke patients. With the device implanted in two patients and a third to come, CorTec now eyes larger trials and a $40m-$50m funding raise.
Medtech Insight - April 9, 2026
CorTec secured US FDA breakthrough device designation for an implantable BCI that restores motor function in stroke patients. With the device implanted in two patients and a third to come, CorTec now eyes larger trials and a $40m-$50m funding raise.
Medtech Insight - April 9, 2026
AI Act Updates Risk ‘Consumer Harm’ From Medical Devices, EU Civil Society Orgs Say
An open letter says recent EU AI Act amendments create “loopholes” that leave some elements of AI-enabled medical devices under-regulated.
Medtech Insight - April 9, 2026
An open letter says recent EU AI Act amendments create “loopholes” that leave some elements of AI-enabled medical devices under-regulated.
Medtech Insight - April 9, 2026
Singapore’s Asian Population Cohort Dataset To Move Forward With Seer’s Proteograph Platform
Precision medicine has a diversity gap – relatively few biomarker datasets to date have strong relevance for non-Western populations. Seer’s Proteograph selection for PRECISE-SG100K, a 100,000-person Singapore cohort, is one of the most direct attempts yet to address that at population scale.
Medtech Insight - April 9, 2026
Precision medicine has a diversity gap – relatively few biomarker datasets to date have strong relevance for non-Western populations. Seer’s Proteograph selection for PRECISE-SG100K, a 100,000-person Singapore cohort, is one of the most direct attempts yet to address that at population scale.
Medtech Insight - April 9, 2026
White House Requests FDA Food Programs Spending Boost But Lower Overall FY 2027 Budget
Request would set FDA’s next budget at $7.23bn after it received just short of $7bn for FY2026; includes $3.306bn in direct appropriations, $47.8m less than in the current budget, and increases total support from user fees by $280m to $3.92bn.
HBW Insight - April 9, 2026
Request would set FDA’s next budget at $7.23bn after it received just short of $7bn for FY2026; includes $3.306bn in direct appropriations, $47.8m less than in the current budget, and increases total support from user fees by $280m to $3.92bn.
HBW Insight - April 9, 2026
Children’s Beauty Boom Signals Caution for Brands In Europe
Beauty products sold in Europe face scrutiny over children’s growing use of skin care and cosmetics as regulators examine safety obligations under EU law and investigate marketing practices targeting minors.
HBW Insight - April 9, 2026
Beauty products sold in Europe face scrutiny over children’s growing use of skin care and cosmetics as regulators examine safety obligations under EU law and investigate marketing practices targeting minors.
HBW Insight - April 9, 2026
Opella Sees Role For Evidence?Based Self?Care In Early MASLD Care
New clinical evidence suggests evidence?based self?care can play a meaningful role in managing MASLD, a common fatty liver condition linked to obesity and diabetes, supporting lifestyle change and opening growth opportunities in an underdeveloped liver health category.
HBW Insight - April 9, 2026
New clinical evidence suggests evidence?based self?care can play a meaningful role in managing MASLD, a common fatty liver condition linked to obesity and diabetes, supporting lifestyle change and opening growth opportunities in an underdeveloped liver health category.
HBW Insight - April 9, 2026
People On The Move: Appointments At Barentz, iHerb, Lonza
A round up of the latest European health & wellness people moves: Barentz names first Human Nutrition EMEA VP; iHerb hires Europe general manager; Lonza adds experience to board.
HBW Insight - April 9, 2026
A round up of the latest European health & wellness people moves: Barentz names first Human Nutrition EMEA VP; iHerb hires Europe general manager; Lonza adds experience to board.
HBW Insight - April 9, 2026
Researchers Make Case To Expand Medication Abortion Access But Note OTC Approval Unlikely
Researchers from Advancing New Standards in Reproductive Health at University of California, San Francisco, say mifepristone/misoprostol medication abortion “likely meets” FDA criteria for OTC sales but acknowledge it’s unlikely they will become available nonprescription.
HBW Insight - April 9, 2026
Researchers from Advancing New Standards in Reproductive Health at University of California, San Francisco, say mifepristone/misoprostol medication abortion “likely meets” FDA criteria for OTC sales but acknowledge it’s unlikely they will become available nonprescription.
HBW Insight - April 9, 2026
‘Eggs Solve All Of Those Problems’ – How Neion Bio Is Seeking To Shake Up Biosimilar Manufacturing
As Neion Bio announced its new technology platform to manufacture recombinant biologics in eggs – accompanied by an initial multi-product biosimilar deal – the firm’s founders set out their goals in an exclusive interview with Generics Bulletin.
Generics Bulletin - April 9, 2026
As Neion Bio announced its new technology platform to manufacture recombinant biologics in eggs – accompanied by an initial multi-product biosimilar deal – the firm’s founders set out their goals in an exclusive interview with Generics Bulletin.
Generics Bulletin - April 9, 2026
Generics Remain ‘Critical Foundation’ For Arcera
Isabel Afonso, CEO of Arcera, talks to Generics Bulletin about how off-patent products remain a “critical foundation” for the UAE-based firm even as it expands into increasingly innovative areas.
Generics Bulletin - April 9, 2026
Isabel Afonso, CEO of Arcera, talks to Generics Bulletin about how off-patent products remain a “critical foundation” for the UAE-based firm even as it expands into increasingly innovative areas.
Generics Bulletin - April 9, 2026
FDA Budget Offers Update On Domestic Incentives For Para IV Filings
The US FDA’s latest annual budget request includes proposals that would allow firms to file Paragraph IV ANDAs more quickly if they manufacture in the US, as well as to make it easier to develop generic drug-device combinations and to deem all biosimilars interchangeable.
Generics Bulletin - April 9, 2026
The US FDA’s latest annual budget request includes proposals that would allow firms to file Paragraph IV ANDAs more quickly if they manufacture in the US, as well as to make it easier to develop generic drug-device combinations and to deem all biosimilars interchangeable.
Generics Bulletin - April 9, 2026
Biocon Launches Held-Back Denosumab Biosimilars In The US
Even though Biocon settled with originator Amgen last autumn, the firm has just now launched its biosimilar rivals to the Prolia/Xgeva brands.
Generics Bulletin - April 9, 2026
Even though Biocon settled with originator Amgen last autumn, the firm has just now launched its biosimilar rivals to the Prolia/Xgeva brands.
Generics Bulletin - April 9, 2026
MSN Deal Ends Trulance Dispute, Signals Launch Pathway
MSN and Bausch have settled their long-running Trulance patent dispute, ending litigation tied to Paragraph IV challenges after trial and parallel PTAB proceedings.
Generics Bulletin - April 9, 2026
MSN and Bausch have settled their long-running Trulance patent dispute, ending litigation tied to Paragraph IV challenges after trial and parallel PTAB proceedings.
Generics Bulletin - April 9, 2026
Deals Shaping The Industry, March 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026
An interactive look at pharma, medtech and diagnostics deals made during March 2026. Data courtesy of Biomedtracker.
In Vivo - April 9, 2026
Podcast: How Israel Is Positioning Itself As A Global Innovation Hub
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026
AION Labs CEO Mati Gill on why Israel - despite active conflict - is emerging as a serious AI-native drug discovery hub for global pharma.
In Vivo - April 9, 2026